(Q39431675)

English

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Matthew J Barth

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Francisco J Hernandez-Ilizaliturri

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Cory Mavis

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Ping-Chiao Tsai

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

John F Gibbs

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

George Deeb

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Myron S Czuczman

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

9 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

156

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

490-498

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Newer monoclonal antibodies for hematological malignancies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgki

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

New approaches of B-cell-directed therapy: beyond rituximab

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Anti-CD20-based therapy of B cell lymphoma: state of the art.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08966.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2011.08966.X

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39431675&oldid=1991785585"